Research Article: Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates
Introduction:
Biosimilar adoption may help lower drug spending for biological therapies [1]. Most biosimilars available in the USA are not interchangeable, meaning that pharmacies may not dispense the biosimilar in place of the reference biologic without a new medical prescription [2]. Increased biosimilar uptake, therefore, depends on physicians prescribing the biosimilar, which is influenced by provider discretion and dependent on health insurance plans incorporating the biosimilar in their drug formularies [3]. Economic…
Read more